NLRP3 and Hepatic fibrosis: Recent research has further shown that age-dependent TET2 mutations promote CHIP and enhance susceptibility to chronic liver diseases by upregulating IL-6 and activating the NLRP3 inflammasome (Wong et al., 2023), indicating a potential mechanistic link between TET2 dysfunction and age-associated liver fibrosis progression.